SCHEMBL1207418

SCHEMBL1207418

COc1cc(Cl)ccc1C(N)=O.COc1cccc(OC)c1-c1ccc(S(=O)(=O)O)cn1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 2/20 0.45
FLT4 P35916 2/20 0.45
KDR P35968 2/20 0.45
CSF1R P07333 3/20 0.42
AVPR2 P30518 1/20 0.41
GPR27 Q9NS67 1/20 0.41
PDE4B Q07343 4/20 0.41
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
MAP2 P11137 1/20 0.39
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
PKM P14618 1/20 0.38
TSHR P16473 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1206402 0.93 FLT1 (0.46) FLT1FLT4KDRCSF1RPDE4B
SCHEMBL1207535 0.93 FLT1 (0.44) FLT1FLT4KDRCSF1RAVPR2
SCHEMBL1206951 0.88 FLT1 (0.43) FLT1FLT4KDRCSF1RAVPR2
SCHEMBL1206968 0.86 FLT1 (0.42) FLT1FLT4KDRCSF1RPDE4B
SCHEMBL1206941 0.86 CSF1R (0.43) CSF1RPDE4BMEN1KMT2A
SCHEMBL1206947 0.82 KDM1A (0.42) FLT1FLT4KDRCSF1RAVPR2
SCHEMBL3465686 0.82 KDM4E (0.45) KDM4EMEN1KMT2A
SCHEMBL1207416 0.81 FLT1 (0.68) FLT1FLT4KDRAVPR2GPR27
SCHEMBL1205856 0.80 MAPK10 (0.41) CSF1R
SCHEMBL4370313 0.80 FLT1 (0.43) FLT1FLT4KDRKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879884-B2 6-(2-Chloro-phenyl)-5-methyl-pyridine-3-sulfonic acid 2-chloro-4-fluoro-benzoylamide; potassium salt, used as antiproliferative, anticarcinogenic or antitumor agents HOFFMANN-LA ROCHE INC. (US) 2011-02-01 US claimed
US-20100256200-A1 ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-07 US claimed
EP-2148861-A1 ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. Hoffmann-Roche AG (CH) 2010-02-03 EP claimed
WO-2008138594-A1 ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2008-11-20 WO claimed
US-7879884-B2 6-(2-Chloro-phenyl)-5-methyl-pyridine-3-sulfonic acid 2-chloro-4-fluoro-benzoylamide; potassium salt, used as antiproliferative, anticarcinogenic or antitumor agents HOFFMANN-LA ROCHE INC. (US) 2011-02-01 US disclosed
US-20100256200-A1 ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-07 US disclosed
EP-2148861-A1 ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. Hoffmann-Roche AG (CH) 2010-02-03 EP disclosed
WO-2008138594-A1 ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256200-A1 ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS ARSA, STS, SULT2A1 FLT1 2946/4885FLT4 3444/4885KDR 3774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.